Cover Image
市場調查報告書

絲胺酸/蘇氨酸蛋白激酶Pim 2:開發中產品分析

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 367845
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
絲胺酸/蘇氨酸蛋白激酶Pim 2:開發中產品分析 Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline Review, H2 2017
出版日期: 2017年11月14日 內容資訊: 英文 40 Pages
簡介

本報告提供以絲胺酸/蘇氨酸蛋白激酶Pim 2為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

絲胺酸/蘇氨酸蛋白激酶Pim 2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Incyte Corp
  • Inflection Biosciences Ltd
  • Jasco Pharmaceuticals LLC
  • Novartis AG
  • Tolero Pharmaceuticals Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1128TDB

Summary:

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Serine/threonine-protein kinase Pim-2 is an enzyme encoded by the PIM2. It is involved in cell survival and cell proliferation. It regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. It mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade.

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 6 and 1 respectively. Report covers products from therapy areas Oncology and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Hematological Tumor, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Colon Cancer, Liver Cancer, Lung Cancer, Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Small Cell Lung Carcinoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report SerineThreonine Protein Kinase Pim 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)
  • The report reviews Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Overview 6
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Therapeutics Development 7
  • Products under Development by Stage of Development 7
  • Products under Development by Therapy Area 8
  • Products under Development by Indication 9
  • Products under Development by Companies 12
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Therapeutics Assessment 15
  • Assessment by Mechanism of Action 15
  • Assessment by Route of Administration 16
  • Assessment by Molecule Type 17
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 18
  • Incyte Corp 18
  • Inflection Biosciences Ltd 18
  • Jasco Pharmaceuticals LLC 19
  • Novartis AG 19
  • Sanofi 20
  • Tolero Pharmaceuticals Inc 20
  • Yakult Honsha Co Ltd 21
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Drug Profiles 22
  • IBL-100 - Drug Profile 22
  • Product Description 22
  • Mechanism Of Action 22
  • R&D Progress 22
  • INCB-53914 - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • JP-11646 - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • LGB-321 - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • PIM-447 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • Small Molecules to Inhibit Pim Kinase for Pancreatic Cancer - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • Small Molecules to Inhibit PIM1 and PIM2 for Oncology - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • TP-3654 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Dormant Products 33
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Discontinued Products 34
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Product Development Milestones 35
  • Featured News & Press Releases 35
  • Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer 35
  • Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology 35
  • Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma 36
  • Apr 04, 2014: Roswell Park to Present Findings on Jasco Pharmaceuticals' Novel PIM Inhibitor at AACR 2014 36
  • Apr 01, 2013: Jasco Pharma To Present Data On PIM Inhibitor Program At AACR Annual Meeting 2013 37
  • Mar 31, 2011: Jasco Pharma To Present Data On Preclinical PIM Inhibitor Program At AACR Annual Meeting 38
  • Appendix 39
  • Methodology 39
  • Coverage 39
  • Secondary Research 39
  • Primary Research 39
  • Expert Panel Validation 39
  • Contact Us 39
  • Disclaimer 40

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017 7
  • Number of Products under Development by Therapy Areas, H2 2017 8
  • Number of Products under Development by Indications, H2 2017 9
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11
  • Number of Products under Development by Companies, H2 2017 12
  • Products under Development by Companies, H2 2017 13
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
  • Number of Products by Stage and Mechanism of Actions, H2 2017 15
  • Number of Products by Stage and Route of Administration, H2 2017 16
  • Number of Products by Stage and Molecule Type, H2 2017 17
  • Pipeline by Incyte Corp, H2 2017 18
  • Pipeline by Inflection Biosciences Ltd, H2 2017 18
  • Pipeline by Jasco Pharmaceuticals LLC, H2 2017 19
  • Pipeline by Novartis AG, H2 2017 20
  • Pipeline by Sanofi, H2 2017 20
  • Pipeline by Tolero Pharmaceuticals Inc, H2 2017 21
  • Pipeline by Yakult Honsha Co Ltd, H2 2017 21
  • Dormant Projects, H2 2017 33
  • Discontinued Products, H2 2017 34

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017 7
  • Number of Products under Development by Therapy Areas, H2 2017 8
  • Number of Products under Development by Top 10 Indications, H2 2017 9
  • Number of Products by Stage and Mechanism of Actions, H2 2017 15
  • Number of Products by Stage and Route of Administration, H2 2017 16
  • Number of Products by Stage and Molecule Type, H2 2017 17
Back to Top